Sherlock Biosciences Named “Fierce 15” Company by FierceMedTech

Cambridge, Mass., March 9, 2020 —

Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced that it has been named by FierceMedTech as one of 2019’s class of Fierce 15, designating it as one of the most promising private companies in the industry.

Sherlock is using Engineering Biology tools, including CRISPR and Synthetic Biology, to create a new generation of molecular diagnostics that can rapidly deliver accurate and inexpensive results for a vast range of needs in virtually any setting.  Sherlock’s mission is to address significant unmet needs in infectious disease, oncology, agriculture and other areas to transform diagnostic testing and global public health. The company takes its name from one of its foundational platform technologies, SHERLOCK™ (Specific High-sensitivity Enzymatic Reporter unLOCKing), a CRISPR-based method for single molecule detection of nucleic acid targets that can be adapted to work on a simple paper strip test, in laboratory equipment, or to provide an electrochemical readout that can be read with a mobile phone. The company is also developing INSPECTR™ (INternal Splint-Pairing Expression Cassette Translation Reaction), a Synthetic Biology-based molecular diagnostics platform that can be programmed to distinguish targets based on a single nucleotide on a paper strip or any other common diagnostic format at room temperature without an instrument.

“We launched Sherlock one year ago with the vision to have a positive impact on human health, including in low-resource settings, where rapid diagnostic testing has the potential to transform lives through better health care and safer food and water,” said Rahul Dhanda, Sherlock’s co-founder, president and CEO. “It’s an honor to be recognized as a ‘Fierce 15’ company, which we believe is a testament to our remarkable team developing fast, reliable and more affordable diagnostic testing that can be deployed anywhere molecular diagnostics are needed.”

The Fierce 15 celebrates the spirit of being “fierce”—championing innovation and creativity, even in the face of intense competition. This is FierceMedTech’s 8th annual Fierce 15 selection. This year’s full list can be viewed at: https://www.fiercebiotech.com/special-report/fiercemedtech-s-2019-fierce-15

“One of the true joys of covering this field is being able to talk with the people driving the next great medical advancements—technologies that may not just change a patient or parent’s life, but also the day-to-day work of clinicians, surgeons, researchers and developers themselves,” said Conor Hale, associate editor of FierceMedTech. “Potential breakthroughs such as these can ripple into new therapies, procedures and interventions, and ultimately more ways to heal more people.”

An internationally recognized daily report reaching a network of over 90,000 medtech industry professionals, FierceMedTech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceMedTech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and competitive market position.

About Sherlock Biosciences

Sherlock Biosciences is dedicated to making molecular diagnostics better, faster and more affordable through Engineering Biology platforms. The company is developing applications of SHERLOCK™, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTRTM, a Synthetic Biology-based molecular diagnostics platform that is instrument free. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests, and disease detection in the field. For more information visit Sherlock.bio. 

 About FierceMedTech

FierceMedTech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. More than 90,000 top industry professionals rely on FierceMedTech for an insider briefing on the day’s top stories.

About Questex

Questex helps people live better and longer. Questex brings people together in the markets that help people live better: travel, hospitality and wellness; the industries that help people live longer: life science and healthcare; and the technologies that enable and fuel these new experiences. We live in the experience economy—connecting our ecosystem through live events, surrounded by data insights and digital communities. We deliver experience and real results. It happens here.

CONTACTS:

Rebecca Willumson
Questex, FierceMedTech
202-824-5050
rwillumson@questex.com

Katie Engleman
1AB, Sherlock Biosciences
katie@1abmedia.com